PharmaCyte Biotech, Inc. PMCB
cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®."
The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC,
will be developed. The current generation of our product candidate is referred to as "CypCaps™."
Scientific Committee (the "Scientific Committee"), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent
Last close
0.36
2026-10-23
Market cap
$3.8M
2026-04-30 share count
52-week range
0.33 - 1.51
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.77
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $391.3K | $438.4K | $407.4K | $468.5K | $690.9K | $916.2K | $301.2K | $460.1K | $2.0M | $1.2M |
| SG&A | $4.9M | $3.9M | $6.1M | $1.1M | $1.1M | $418.1K | $1.2M | $1.4M | $1.8M | $744.8K |
| Total operating expenses | $6.9M | $4.4M | $8.5M | $6.5M | $4.4M | $3.6M | $3.8M | $4.1M | $7.0M | $4.4M |
| Operating income | -$6.9M | -$4.4M | -$8.5M | -$6.5M | -$4.4M | -$3.6M | -$3.8M | -$4.1M | -$7.0M | -$4.4M |
| Interest expense | — | — | — | $0 | $509 | $3.0K | $453 | $0 | $0 | $1.5K |
| Pre-tax income | -$19.4M | $30.7M | $333.8K | -$4.3M | -$4.2M | -$3.6M | -$3.8M | -$4.1M | -$6.8M | -$4.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.4M | $30.7M | $333.8K | -$4.3M | -$4.2M | -$3.6M | -$3.8M | -$4.1M | -$6.8M | -$4.4M |
| EPS, basic | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | — | — | — | — |
| EPS, diluted | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | -4.23 | 0.00 | -0.01 | -0.01 |
| Shares, diluted (wtd. avg.) | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | 1.4M | 903,812 | 1.10B | 968.6M | 845.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.6M | $15.2M | $50.2M | $68.0M | $85.4M | $2.2M | $894.9K | — | — | — |
| Short-term investments | $254.0K | $366.3K | $0 | — | — | — | — | — | — | — |
| Total current assets | $37.4M | $22.4M | $50.4M | $68.1M | $85.5M | $2.3M | $1.0M | $653.4K | $1.3M | $3.5M |
| Other intangibles | $0 | $1.5M | $1.5M | $3.5M | $3.5M | — | — | — | — | — |
| Total assets | $46.8M | $55.2M | $59.9M | $73.3M | $90.6M | $7.4M | $6.2M | $5.8M | $6.4M | $8.7M |
| Accounts payable | $271.1K | $399.2K | $389.4K | $128.3K | $205.4K | $172.3K | $185.8K | $121.9K | $352.6K | $365.6K |
| Total current liabilities | $826.4K | $2.9M | $7.4M | $586.6K | $704.4K | $724.8K | $1.0M | $742.9K | $644.2K | $580.2K |
| Total liabilities | $11.8M | $3.3M | $20.4M | $586.6K | $704.4K | $724.8K | $1.1M | $742.9K | $644.2K | $580.2K |
| Retained earnings | -$104.4M | -$85.0M | -$115.6M | -$116.0M | -$111.6M | -$107.4M | -$103.9M | -$100.0M | -$96.0M | -$89.1M |
| Total equity | $33.3M | $51.9M | $27.6M | $72.7M | $89.9M | $6.7M | $5.1M | $5.0M | $5.8M | $8.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.2M | -$3.0M | -$2.2M | -$3.8M | -$4.1M | -$3.3M | -$2.3M | -$2.9M | -$5.1M | -$3.3M |
| Stock-based compensation | $892.5K | $0 | $674.7K | $7.3K | $33.1K | $194.3K | $368.6K | $293.3K | $580.4K | $420.5K |
| Investing cash flow | $2.0M | -$7.0M | -$5.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $6.6M | -$25.0M | -$10.7M | -$13.6M | $87.3M | $4.6M | $2.7M | $2.3M | $2.7M | $4.9M |
| Buybacks | $401.6K | $2.5M | $28.2M | $13.6M | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-005836.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$4.4M | -$6.8M | -$4.1M | -$3.8M | -$3.6M | -$4.2M | -$4.3M | $333.8K | $30.7M | -$19.4M |
Recent filings and events
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |